Bruker Corporation Logo

Bruker Corporation

BRKR

(2.5)
Stock Price

66,80 USD

12.48% ROA

33.81% ROE

33x PER

Market Cap.

9.941.411.598,00 USD

99.39% DER

0.28% Yield

14.41% NPM

Bruker Corporation Stock Analysis

Bruker Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bruker Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (28.22%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

4 DER

The stock maintains a fair debt to equity ratio (99%), indicating a reasonable balance between the money it owes and the ownership it possesses.

5 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

6 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

7 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (636) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 PBV

The stock's high Price-to-Book Value (P/BV) ratio (7.19x) suggests it's overvalued, potentially making it an expensive investment.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Bruker Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bruker Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Bruker Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bruker Corporation Revenue
Year Revenue Growth
1998 42.207.000
1999 64.690.450 34.76%
2000 76.602.000 15.55%
2001 92.691.000 17.36%
2002 116.368.000 20.35%
2003 260.679.000 55.36%
2004 284.416.000 8.35%
2005 297.569.000 4.42%
2006 435.834.000 31.72%
2007 547.576.000 20.41%
2008 1.107.100.000 50.54%
2009 1.114.500.000 0.66%
2010 1.304.900.000 14.59%
2011 1.651.700.000 21%
2012 1.791.400.000 7.8%
2013 1.839.400.000 2.61%
2014 1.808.900.000 -1.69%
2015 1.623.800.000 -11.4%
2016 1.611.300.000 -0.78%
2017 1.765.900.000 8.75%
2018 1.895.600.000 6.84%
2019 2.072.600.000 8.54%
2020 1.987.500.000 -4.28%
2021 2.417.900.000 17.8%
2022 2.530.700.000 4.46%
2023 2.971.200.000 14.83%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bruker Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 15.138.114 100%
2000 20.033.000 24.43%
2001 18.468.000 -8.47%
2002 20.734.000 10.93%
2003 38.026.000 45.47%
2004 43.219.000 12.02%
2005 41.357.000 -4.5%
2006 49.959.000 17.22%
2007 58.466.000 14.55%
2008 133.800.000 56.3%
2009 126.400.000 -5.85%
2010 141.400.000 10.61%
2011 177.200.000 20.2%
2012 195.300.000 9.27%
2013 190.500.000 -2.52%
2014 174.200.000 -9.36%
2015 145.700.000 -19.56%
2016 149.000.000 2.21%
2017 162.700.000 8.42%
2018 173.400.000 6.17%
2019 187.700.000 7.62%
2020 198.000.000 5.2%
2021 220.800.000 10.33%
2022 235.900.000 6.4%
2023 285.200.000 17.29%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bruker Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 14.756.403 100%
2000 20.248.000 27.12%
2001 27.718.000 26.95%
2002 33.815.000 18.03%
2003 77.755.000 56.51%
2004 76.375.000 -1.81%
2005 73.812.000 -3.47%
2006 112.989.000 34.67%
2007 140.041.000 19.32%
2008 254.500.000 44.97%
2009 69.500.000 -266.19%
2010 303.100.000 77.07%
2011 406.600.000 25.45%
2012 442.400.000 8.09%
2013 437.900.000 -1.03%
2014 451.000.000 2.9%
2015 392.200.000 -14.99%
2016 390.500.000 -0.44%
2017 415.900.000 6.11%
2018 444.700.000 6.48%
2019 500.200.000 11.1%
2020 477.800.000 -4.69%
2021 564.500.000 15.36%
2022 610.800.000 7.58%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bruker Corporation EBITDA
Year EBITDA Growth
1998 -161.000
1999 7.072.432 102.28%
2000 5.087.000 -39.03%
2001 8.974.000 43.31%
2002 24.206.000 62.93%
2003 15.402.000 -57.16%
2004 8.675.000 -77.54%
2005 19.246.000 54.93%
2006 51.665.000 62.75%
2007 72.781.000 29.01%
2008 163.300.000 55.43%
2009 397.500.000 58.92%
2010 161.500.000 -146.13%
2011 158.600.000 -1.83%
2012 217.500.000 27.08%
2013 238.100.000 8.65%
2014 209.300.000 -13.76%
2015 228.600.000 8.44%
2016 257.300.000 11.15%
2017 298.300.000 13.74%
2018 346.800.000 13.99%
2019 383.000.000 9.45%
2020 353.600.000 -8.31%
2021 516.700.000 31.57%
2022 550.400.000 6.12%
2023 642.000.000 14.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bruker Corporation Gross Profit
Year Gross Profit Growth
1998 42.207.000
1999 36.559.351 -15.45%
2000 41.015.000 10.86%
2001 49.103.000 16.47%
2002 60.496.000 18.83%
2003 115.845.000 47.78%
2004 118.476.000 2.22%
2005 125.807.000 5.83%
2006 199.334.000 36.89%
2007 253.138.000 21.25%
2008 505.000.000 49.87%
2009 518.600.000 2.62%
2010 606.000.000 14.42%
2011 752.500.000 19.47%
2012 831.400.000 9.49%
2013 805.200.000 -3.25%
2014 763.300.000 -5.49%
2015 708.600.000 -7.72%
2016 742.500.000 4.57%
2017 813.000.000 8.67%
2018 900.000.000 9.67%
2019 995.300.000 9.58%
2020 939.800.000 -5.91%
2021 1.209.600.000 22.3%
2022 1.305.700.000 7.36%
2023 1.531.200.000 14.73%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bruker Corporation Net Profit
Year Net Profit Growth
1998 0
1999 1.249.519 100%
2000 2.250.000 44.47%
2001 3.637.000 38.14%
2002 -6.200.000 158.66%
2003 -17.554.000 64.68%
2004 -7.831.000 -124.16%
2005 3.646.000 314.78%
2006 18.481.000 80.27%
2007 31.529.000 41.38%
2008 64.900.000 51.42%
2009 81.200.000 20.07%
2010 95.400.000 14.88%
2011 92.300.000 -3.36%
2012 77.500.000 -19.1%
2013 80.100.000 3.25%
2014 56.700.000 -41.27%
2015 101.600.000 44.19%
2016 153.600.000 33.85%
2017 78.600.000 -95.42%
2018 179.700.000 56.26%
2019 197.200.000 8.87%
2020 157.800.000 -24.97%
2021 277.100.000 43.05%
2022 296.600.000 6.57%
2023 352.400.000 15.83%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bruker Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 0 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 100%
2019 1 0%
2020 1 0%
2021 2 0%
2022 2 50%
2023 2 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bruker Corporation Free Cashflow
Year Free Cashflow Growth
1999 1.201.556
2000 -5.783.000 120.78%
2001 -29.070.000 80.11%
2002 -27.306.000 -6.46%
2003 -11.576.000 -135.88%
2004 -8.153.000 -41.98%
2005 38.981.000 120.92%
2006 30.070.000 -29.63%
2007 12.130.000 -147.9%
2008 59.500.000 79.61%
2009 133.500.000 55.43%
2010 124.200.000 -7.49%
2011 33.300.000 -272.97%
2012 60.300.000 44.78%
2013 94.700.000 36.33%
2014 80.500.000 -17.64%
2015 195.000.000 58.72%
2016 93.700.000 -108.11%
2017 110.700.000 15.36%
2018 190.500.000 41.89%
2019 140.400.000 -35.68%
2020 235.000.000 40.26%
2021 190.400.000 -23.42%
2022 143.000.000 -33.15%
2023 17.200.000 -731.4%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bruker Corporation Operating Cashflow
Year Operating Cashflow Growth
1999 5.437.233
2000 -202.000 2791.7%
2001 -11.475.000 98.24%
2002 -11.390.000 -0.75%
2003 -6.085.000 -87.18%
2004 -889.000 -584.48%
2005 42.193.000 102.11%
2006 37.693.000 -11.94%
2007 28.209.000 -33.62%
2008 106.900.000 73.61%
2009 149.800.000 28.64%
2010 156.100.000 4.04%
2011 87.700.000 -77.99%
2012 133.100.000 34.11%
2013 145.000.000 8.21%
2014 114.300.000 -26.86%
2015 229.200.000 50.13%
2016 130.800.000 -75.23%
2017 154.400.000 15.28%
2018 239.700.000 35.59%
2019 213.400.000 -12.32%
2020 333.200.000 35.95%
2021 282.400.000 -17.99%
2022 262.000.000 -7.79%
2023 44.100.000 -494.1%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bruker Corporation Capital Expenditure
Year Capital Expenditure Growth
1999 4.235.677
2000 5.581.000 24.11%
2001 17.595.000 68.28%
2002 15.916.000 -10.55%
2003 5.491.000 -189.86%
2004 7.264.000 24.41%
2005 3.212.000 -126.15%
2006 7.623.000 57.86%
2007 16.079.000 52.59%
2008 47.400.000 66.08%
2009 16.300.000 -190.8%
2010 31.900.000 48.9%
2011 54.400.000 41.36%
2012 72.800.000 25.27%
2013 50.300.000 -44.73%
2014 33.800.000 -48.82%
2015 34.200.000 1.17%
2016 37.100.000 7.82%
2017 43.700.000 15.1%
2018 49.200.000 11.18%
2019 73.000.000 32.6%
2020 98.200.000 25.66%
2021 92.000.000 -6.74%
2022 119.000.000 22.69%
2023 26.900.000 -342.38%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bruker Corporation Equity
Year Equity Growth
1998 10.340.000
1999 10.057.649 -2.81%
2000 124.172.000 91.9%
2001 127.547.000 2.65%
2002 126.378.000 -0.93%
2003 202.426.000 37.57%
2004 217.275.000 6.83%
2005 207.802.000 -4.56%
2006 191.466.000 -8.53%
2007 258.659.000 25.98%
2008 311.900.000 17.07%
2009 418.800.000 25.53%
2010 527.400.000 20.59%
2011 624.900.000 15.6%
2012 706.600.000 11.56%
2013 850.200.000 16.89%
2014 771.700.000 -10.17%
2015 732.900.000 -5.29%
2016 693.100.000 -5.74%
2017 733.500.000 5.51%
2018 913.600.000 19.71%
2019 927.400.000 1.49%
2020 988.700.000 6.2%
2021 1.084.800.000 8.86%
2022 1.131.800.000 4.15%
2023 1.244.200.000 9.03%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bruker Corporation Assets
Year Assets Growth
1998 63.841.000
1999 67.309.060 5.15%
2000 184.554.000 63.53%
2001 189.074.000 2.39%
2002 203.102.000 6.91%
2003 351.031.000 42.14%
2004 371.547.000 5.52%
2005 360.887.000 -2.95%
2006 433.187.000 16.69%
2007 553.213.000 21.7%
2008 1.116.300.000 50.44%
2009 1.172.000.000 4.75%
2010 1.549.800.000 24.38%
2011 1.710.500.000 9.39%
2012 1.856.400.000 7.86%
2013 1.988.300.000 6.63%
2014 1.864.800.000 -6.62%
2015 1.730.900.000 -7.74%
2016 1.812.900.000 4.52%
2017 1.948.500.000 6.96%
2018 2.128.600.000 8.46%
2019 2.771.500.000 23.2%
2020 3.047.900.000 9.07%
2021 3.650.000.000 16.5%
2022 3.618.500.000 -0.87%
2023 3.818.200.000 5.23%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bruker Corporation Liabilities
Year Liabilities Growth
1998 53.501.000
1999 57.251.411 6.55%
2000 60.382.000 5.18%
2001 61.527.000 1.86%
2002 76.724.000 19.81%
2003 148.481.000 48.33%
2004 154.079.000 3.63%
2005 152.852.000 -0.8%
2006 241.482.000 36.7%
2007 294.016.000 17.87%
2008 803.600.000 63.41%
2009 753.200.000 -6.69%
2010 1.022.400.000 26.33%
2011 1.085.600.000 5.82%
2012 1.146.800.000 5.34%
2013 1.138.100.000 -0.76%
2014 1.093.100.000 -4.12%
2015 998.000.000 -9.53%
2016 1.119.800.000 10.88%
2017 1.215.000.000 7.84%
2018 1.223.500.000 0.69%
2019 1.854.400.000 34.02%
2020 2.072.300.000 10.51%
2021 2.565.200.000 19.21%
2022 2.486.700.000 -3.16%
2023 2.574.000.000 3.39%

Bruker Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
19.23
Net Income per Share
2.18
Price to Earning Ratio
33x
Price To Sales Ratio
3.53x
POCF Ratio
34.67
PFCF Ratio
48.76
Price to Book Ratio
8.58
EV to Sales
3.83
EV Over EBITDA
18.22
EV to Operating CashFlow
35.55
EV to FreeCashFlow
52.95
Earnings Yield
0.03
FreeCashFlow Yield
0.02
Market Cap
9,94 Bil.
Enterprise Value
10,80 Bil.
Graham Number
20.25
Graham NetNet
-9.47

Income Statement Metrics

Net Income per Share
2.18
Income Quality
0.94
ROE
0.27
Return On Assets
0.1
Return On Capital Employed
0.14
Net Income per EBT
0.79
EBT Per Ebit
1.23
Ebit per Revenue
0.15
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0.18
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.51
Operating Profit Margin
0.15
Pretax Profit Margin
0.18
Net Profit Margin
0.14

Dividends

Dividend Yield
0
Dividend Yield %
0.28
Payout Ratio
0.09
Dividend Per Share
0.2

Operating Metrics

Operating Cashflow per Share
2.07
Free CashFlow per Share
1.39
Capex to Operating CashFlow
-0.33
Capex to Revenue
-0.04
Capex to Depreciation
-0.99
Return on Invested Capital
0.14
Return on Tangible Assets
0.12
Days Sales Outstanding
62.86
Days Payables Outstanding
48.37
Days of Inventory on Hand
244.13
Receivables Turnover
5.81
Payables Turnover
7.55
Inventory Turnover
1.5
Capex per Share
-0.68

Balance Sheet

Cash per Share
2,48
Book Value per Share
8,37
Tangible Book Value per Share
2.67
Shareholders Equity per Share
8.37
Interest Debt per Share
8.09
Debt to Equity
0.99
Debt to Assets
0.32
Net Debt to EBITDA
1.44
Current Ratio
1.89
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,54 Bil.
Invested Capital
0.99
Working Capital
0,96 Bil.
Intangibles to Total Assets
0.33
Average Receivables
0,47 Bil.
Average Payables
0,19 Bil.
Average Inventory
915300000
Debt to Market Cap
0.12

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bruker Corporation Dividends
Year Dividends Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Bruker Corporation Profile

About Bruker Corporation

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

CEO
Dr. Frank H. Laukien Ph.D.
Employee
9.707
Address
40 Manning Road
Billerica, 01821

Bruker Corporation Executives & BODs

Bruker Corporation Executives & BODs
# Name Age
1 Dr. Burkhard Prause Ph.D.
President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc.
70
2 Mr. J. Brent Alldredge J.D.
General Counsel & Secretary
70
3 Dr. Frank H. Laukien Ph.D.
Chairman, Chief Executive Officer & President
70
4 Mr. Juergen Srega
President of Bruker CALID Group & Bruker Daltonics Division
70
5 Dr. Falko Busse Ph.D.
President of Bruker BioSpin Group
70
6 Stacey Desrochers
Treasurer & Director of Investor Relations
70
7 Dr. Mark R. Munch Ph.D.
Corporate Executive Vice President and President of Bruker Nano Group & Corporate
70
8 Mr. Justin Joseph Ward
Senior Director of Investor Relations & Corporate Development
70
9 Mr. Gerald N. Herman
Executive Vice President & Chief Financial Officer
70

Bruker Corporation Competitors